CVRx Inc Dossier - Source-backed chat

CVRx Inc

CVRXNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.89

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $1.53Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $40.8M

Enterprise Value $34.7M

Shares Outstanding 26.5M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

CVRx, Inc. is a commercial-stage medical device company commercializing its proprietary Barostim system, the first FDA-approved neuromodulation technology designed to treat heart failure symptoms. The investment thesis centers on a major regulatory and commercial inflection point: the transition from Category III to Category I CPT codes effective January 1, 2026. This transition eliminates automatic insurance denials, improves prior authorization predictability, and fairly compensates physicians, directly addressing historical adoption barriers. While the company has faced salesforce restructuring challenges, early 2026 metrics show positive momentum with expanding active implanting centers and rising prior authorization approval rates. Furthermore, the newly initiated BENEFIT-HF clinical trial represents a massive long-term catalyst that could triple the company's addressable market by expanding Barostim's indication to a broader heart failure population.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$6.00

Mean target$11.17

High · most bullish analyst$14.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$6.0015%

Persistent operational friction within the sales organization delays territory productivity. Medicare Advantage administrative reviews tighten further, offsetting the benefits of the Category I CPT codes. Slower enrollment in the BENEFIT-HF trial increases the long-term cash burn, forcing highly dilutive future financing.

Base CaseCentral scenario

$11.1760%

Matches the consensus mean

Steady commercial execution where Category I CPT codes provide predictable reimbursement, supporting 20% year-over-year revenue growth. The salesforce stabilizes, active implanting centers expand incrementally, and the BENEFIT-HF trial progresses on its multi-year timeline. Cash reserves remain sufficient to fund operations without immediate highly dilutive equity raises.

Bull CaseUpside scenario

$14.0025%

Rapid commercial acceleration driven by seamless Category I CPT code adoption, leading to a faster-than-expected ramp-up in active implanting centers and territory manager productivity. Prior authorization approval rates exceed 60%, and the BENEFIT-HF trial achieves rapid enrollment, positioning the company for long-term market dominance in heart failure neuromodulation.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Reimbursement Inflection: Transition to Category I CPT codes as of January 1, 2026, significantly reduces administrative barriers and improves prior authorization predictability.
Addressable Market Expansion: The landmark BENEFIT-HF trial, supported by CMS Category B IDE coverage, has the potential to triple the indicated patient population for Barostim.
Strong Gross Margins: High gross margins (87% in Q1 2026) reflect strong pricing power and manufacturing efficiencies.
Strengthened Balance Sheet: Recent debt facility amendment extends maturity to 2031 and provides access to additional capital to support commercial expansion.

Key Investment Risks

Single-Product Concentration: High reliance on a single product platform (Barostim) for all commercial revenue.
Salesforce Execution: History of operational challenges and restructuring within the sales organization, with a significant portion of territory managers still ramping up productivity.
Ongoing Losses and Cash Burn: The company continues to generate net losses ($13.1 million in Q1 2026) and may require future financing, risking shareholder dilution.
Reimbursement and Regulatory Hurdles: Continued dependence on favorable coverage policies from government health authorities and private insurers.

Thesis Invalidation Triggers

A sustained decline in the Medicare Advantage prior authorization approval rate below 40%.
Failure to expand the number of active U.S. implanting centers quarter-over-quarter.
Significant delays or safety signals emerging from the BENEFIT-HF clinical trial.
Unexpected executive leadership transitions, particularly within the commercial or clinical teams.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.